Exact Sciences Announces Second Quarter 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Exact Sciences (EXAS) Misses Q2 EPS by 27c, Revenue Beats
July 28, 2021 4:09 PM EDTExact Sciences (NASDAQ: EXAS) reported Q2 EPS of ($1.03), $0.27 worse than the analyst estimate of ($0.76). Revenue for the quarter came in at $434.8 million versus the consensus estimate of $421.28 million.
GUIDANCE:
Exact Sciences sees FY2021 revenue of $1.71-1.75 billion, versus the consensus of $1.72... More



